Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Research Report 2021

1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Overview

• 1.1 Product Overview and Scope of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
• 1.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type
  • 1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Immune DTaP Vaccine
  • 1.2.3 Therapy DTaP Vaccine
• 1.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application
  • 1.3.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Comparison by Application: (2021-2027)
  • 1.3.2 Adult
  • 1.3.3 Pediatric
• 1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Estimates and Forecasts
  • 1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2016-2027
  • 1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2016-2027
  • 1.4.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region: 2016 Versus 2021 Versus 2027

2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competition by Manufacturers

• 2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Sites, Area Served, Product Type
• 2.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation and Trends
  • 2.5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue
  • 2.5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Retrospective Market Scenario by Region

• 3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  • 3.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  • 3.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  • 3.4.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  • 3.4.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
  • 3.5.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  • 3.6.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  • 3.6.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  • 3.7.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Analysis by Type

• 4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2016-2021)
• 4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2016-2021)
• 4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2016-2021)

5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Analysis by Application

• 5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2016-2021)
• 5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2016-2021)
• 5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Sanofi Pasteur
  • 6.1.1 Sanofi Pasteur Corporation Information
  • 6.1.2 Sanofi Pasteur Description and Business Overview
  • 6.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Sanofi Pasteur Product Portfolio
  • 6.1.5 Sanofi Pasteur Recent Developments/Updates
• 6.2 GlaxoSmithKline
  • 6.2.1 GlaxoSmithKline Corporation Information
  • 6.2.2 GlaxoSmithKline Description and Business Overview
  • 6.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 GlaxoSmithKline Product Portfolio
  • 6.2.5 GlaxoSmithKline Recent Developments/Updates
• 6.3 Protein Sciences Corporation
  • 6.3.1 Protein Sciences Corporation Corporation Information
  • 6.3.2 Protein Sciences Corporation Description and Business Overview
  • 6.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Protein Sciences Corporation Product Portfolio
  • 6.3.5 Protein Sciences Corporation Recent Developments/Updates
• 6.4 Novartis AG
  • 6.4.1 Novartis AG Corporation Information
  • 6.4.2 Novartis AG Description and Business Overview
  • 6.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Novartis AG Product Portfolio
  • 6.4.5 Novartis AG Recent Developments/Updates
• 6.5 Seqirus
  • 6.5.1 Seqirus Corporation Information
  • 6.5.2 Seqirus Description and Business Overview
  • 6.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Seqirus Product Portfolio
  • 6.5.5 Seqirus Recent Developments/Updates
• 6.6 Merck Sharp & Dohme Corp
  • 6.6.1 Merck Sharp & Dohme Corp Corporation Information
  • 6.6.2 Merck Sharp & Dohme Corp Description and Business Overview
  • 6.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Merck Sharp & Dohme Corp Product Portfolio
  • 6.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates
• 6.7 Astellas Pharma US
  • 6.6.1 Astellas Pharma US Corporation Information
  • 6.6.2 Astellas Pharma US Description and Business Overview
  • 6.6.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Astellas Pharma US Product Portfolio
  • 6.7.5 Astellas Pharma US Recent Developments/Updates
• 6.8 Pfizer Inc
  • 6.8.1 Pfizer Inc Corporation Information
  • 6.8.2 Pfizer Inc Description and Business Overview
  • 6.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Pfizer Inc Product Portfolio
  • 6.8.5 Pfizer Inc Recent Developments/Updates
• 6.9 Johnson & Johnson
  • 6.9.1 Johnson & Johnson Corporation Information
  • 6.9.2 Johnson & Johnson Description and Business Overview
  • 6.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Johnson & Johnson Product Portfolio
  • 6.9.5 Johnson & Johnson Recent Developments/Updates
• 6.10 Lanzhou Institute of Biological Products Co., Ltd
  • 6.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
  • 6.10.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
  • 6.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Lanzhou Institute of Biological Products Co., Ltd Product Portfolio
  • 6.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
• 6.11 AstraZeneca
  • 6.11.1 AstraZeneca Corporation Information
  • 6.11.2 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Description and Business Overview
  • 6.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 AstraZeneca Product Portfolio
  • 6.11.5 AstraZeneca Recent Developments/Updates
• 6.12 Emergent BioSolutions Inc
  • 6.12.1 Emergent BioSolutions Inc Corporation Information
  • 6.12.2 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Description and Business Overview
  • 6.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Emergent BioSolutions Inc Product Portfolio
  • 6.12.5 Emergent BioSolutions Inc Recent Developments/Updates

7 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Cost Analysis

• 7.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
• 7.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
• 8.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers

9 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics

• 9.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
• 9.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Growth Drivers
• 9.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
• 9.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints

10 Global Market Forecast

• 10.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type (2022-2027)
• 10.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application (2022-2027)
• 10.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List